News

Southern Spine Announces John E. Hart as President and Chief Executive Officer

Southern Spine, LLC, an ISO 13485:2003 certified manufacturer of implants and instruments for spinal surgery, announced that John E Hart has been named as President and Chief Executive Officer to lead the company.

Hart has more than 35 years of executive leadership experience in the medical device, life science and biologics fields serving in general management, marketing, sales, business development and operational management roles. Most recently, Hart served as a member of the turnaround team at Conmed Corporation, where he led the Cardiology and Critical Care Division to double digit revenue and profit growth. He also led the Healthcare Solutions team which was responsible for corporate, national and government accounts. Prior to that he served as Chief Operating Office for ISTO Technologies, Inc. for 3 years and President and CEO of Vidar Systems Corporation for 5 years. Both companies achieved successful exits.

“John is the right leader for Southern Spine,” said Hugh F. Smisson, III M.D., Southern Spine’s Chairman of the Board. “John’s extensive background in management, sales, marketing and business development should help strengthen our partnerships, develop strategic alliances, expand our sales presence and grow our profitability in the spine and pain markets.”

“I am very excited to be joining the Southern Spine team,” said John Hart. “I believe that Southern Spine’s great products and talented team will be key factors in leading the company’s next chapter for success and growth with the exciting Stabilink® MIS Interlaminar Spinal Fixation System.

John has also held senior executive positions in Fortune 500 companies, including Stryker Orthopaedics (Stryker Corporation) and U.S. Surgical (Covidien – now Medtronic).

John holds a BS degree from The College of New Jersey and an MBA from Southern New Hampshire University. He is a member of the Board of Directors for Virginia Bio.

Recent News

10/21/2025

SRI multi-party team selected as an awardee by ARPA-H to develop at-home screening for ≥30 types of cancers

SRI, along with research partners Foothold Labs and Triple Ring Technologies and commercial partner Beacon Dx Health, has been awarded up to $34 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop technology as part of the POSEIDON (Platform Optimizing SynBio for Early Intervention and Detection in Oncology) program. This pioneering program

10/21/2025

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, QRX003, for the treatment of Netherton Syndrome. The designation follows previously granted Orphan

10/20/2025

Merck Breaks Ground on $3 Billion Center of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the start of construction for a $3 billion, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70 billion investment beginning in 2025 to